Quantitative determination of lisinopril in human plasma by high performance liquid chromatography–tandem mass spectrometry and its application in a pharmacokinetic study

Abstract

A rapid, selective and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed to determine lisinopril in human plasma. Sample pretreatment involved a one-step protein precipitation with methanol of 0.1 mL plasma. Analysis was performed on an Inertsil ODS-3 column (2.1 × 50 mm i.d., 3 µm) with mobile phase consisting of methanol-water (containing 0.2% formic acid; 55:45, v/v). The detection was performed on a triple quadrupole tandem mass spectrometer in multiple reaction monitoring mode via an electrospray ionization source. Each plasma sample was chromatographed within 2.5 min. The linear calibration curves for lisinopril were obtained in the concentration range of 1.03-206 ng/mL (r(2) ≥ 0.99) with a lower limit of quantification of 1.03 ng/mL. The intra- and inter-day precisions (relative standard deviation) were not higher than 11%, and accuracy (relative error) was within ±6.8%, determined from quality control samples for lisinopril, which corresponded to the guidance of the Food and Drug Administration. The method described herein was fully validated and successfully applied to the pharmacokinetic study of lisinopril tablets in healthy male volunteers after oral administration.

Validated LC‐MS/MS method for the simultaneous determination of hyperoside and 2′′–O‐galloylhyperin in rat plasma: application to a pharmacokinetic study in rats

“…The matrix effect was determined by comparing the analyte peak areas of the QC solutions dissolved in the supernatant of the processed blank rat plasma with those of the standard solutions. In general, values in the range of 85–115% are considered to indicate the absence of significant matrix effect (Qin et al ., ; Chen et al ., ). The ratios of the peak responses for 2′′– O ‐galloylhyperin were 103.3 ± 4.3, 105.4 ± 5.5 and 101.2 ± 3.2% at 5.00, 200 and 3600 ng/mL, respectively.…”

Fast and sensitive LC–MS/MS method for the simultaneous determination of lisinopril and hydrochlorothiazide in human plasma

“…Several methods are available to determine LIS as a single analyte in human plasma or urine by high-performance liquid chromatography (HPLC) with fluorescence [5] , [6] , ultraviolet (UV) [6] or mass detection [7] , [8] , [9] , [10] , [11] , [12] , [13] . Few other methods present simultaneous determination of LIS together with other histamine H 2 antagonists [14] and other antihypertensive medications [15] , [16] in pharmaceutical formulations and human serum.…”

Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection

“…The disposition of lisinopril in children is similar to adults, with peak concentrations observed within 6 hours after dosing and the extent of drug absorption ∼28% . The drug is not appreciably bound to plasma proteins and, thus, its disposition appears to be unaltered by low serum albumin levels . Lisinopril is not appreciably metabolized, and it is excreted largely unchanged in the urine via glomerular filtration with no apparent contribution via active tubular secretion .…”